Researchers used molecular imaging to visualize changes in the brains of heavy marijuana smokers versus non-smokers, finding a decreased number of cannabinoid CB1 receptors. Chronic cannabis smoking caused downregulation of these receptors, but they returned to normal when subjects stopped smoking.
A new near-infrared fluorescence agent has been developed to detect deep vein thrombosis, a potentially deadly cardiovascular disease. The agent uses a biomarker that targets fibrin, a protein involved in blood clot formation, and has shown high-resolution imaging capabilities in phase II clinical trials.
A study found that non-gated PET imaging with 4D computed tomography can produce more accurate tumor imaging for patients with irregular breathing. This approach may improve overall accuracy of tumor detection and inform clinicians about appropriate treatments.
A new study found a significant correlation between high BMI and decreased aromatase availability in the brains of overweight subjects. This suggests that low estrogen levels may lead to reduced control over appetite and food intake, resulting in weight gain.
A study found that gamma imaging outperformed ultrasound in detecting breast cancer, especially in women with dense breast tissue. Gamma imaging provided 100% sensitivity and 82% specificity, leading to a better prognosis for breast cancer patients.
A new molecular imaging agent has been developed to detect tumor angiogenesis, a process of rapid blood vessel growth associated with malignant cancers. The agent, which targets the CD105 protein biomarker, shows promising results in early studies, including high uptake by tumors in mice.
Researchers combined two molecular imaging agents to create a powerful new tool for acquiring information about the extent of a patient's cancer. The results showed that combined 18F NaF and 18F FDG PET/CT imaging provided good-quality imaging of both skeletal and extra-skeletal malignant lesions from various cancers.
Researchers developed a new alpha-emitter-based therapy that effectively targets and cures neuroendocrine tumors without harming healthy tissues. The treatment, called 213Bi-DOTATOC peptide receptor alpha-therapy, showed promising results in patients with liver metastases resistant to beta-particle peptide therapy.
A study of 191 diabetic patients found that dual isotope SPECT/CT accurately diagnosed osteomyelitis and soft tissue infections, leading to conservative treatment planning and limb salvage in 72% of cases. This imaging method has the potential to reduce unnecessary amputations and improve patient outcomes.
Researchers developed a molecular imaging technique that can detect reduced blood flow in diabetic hearts, potentially saving lives. The study found that this method is safe and beneficial for predicting cardiac events in diabetic patients suspected of having ischemic heart disease.
Researchers found that PET/CT imaging with the radiotracer 18F-FDG successfully detected 84% of benign and malignant tumors in patients with adnexal masses. This technology helps predict cancer stage and provide better treatment options for women diagnosed with ovarian cancer.
A new imaging agent called 18F FPPRGD2 targets breast tumor development by detecting angiogenesis, a process that forms new blood vessels in tissues. This allows for better clinical decisions and earlier identification of patients who are ideal candidates for aggressive therapies.
A study published at SNM's 58th Annual Meeting found that molecular imaging, specifically FDG-PET scans, can effectively diagnose the cause of fever of unknown origin. The research suggests that FDG-PET may improve patients' prognosis and cut healthcare costs by providing a non-invasive diagnostic tool.
Researchers have successfully used oatmeal products radiolabeled with a medical isotope to image stomach emptying in molecular imaging studies. The study demonstrated that prior boiling and labeling of oatmeal improves radiolabeling efficiency, making it an effective alternative to egg meal for patients with dietary restrictions.
Researchers are advancing positron emission tomography (PET) as an effective method of early detection for Alzheimer's disease. Studies show that amyloid plaques build up slowly and are often present in healthy older individuals, with significant buildup linked to quicker memory decline and brain atrophy.
A molecular imaging procedure using PET/CT and F18 NaF radiotracer accurately diagnoses and manages chronic back pain by pinpointing the source of abnormal bone reaction. In a study, this method was found to be highly effective in more than 85% of cases, providing relief for patients with hardware implants or bone grafts.
A recent study published in The Journal of Nuclear Medicine found that PET scans can help determine earlier if treatment for tuberculosis is working or if the disease is multidrug-resistant. This technology has the potential to become a valuable clinical adjunct to genotypic and phenotypic tests, improving patient outcomes.
Researchers analyzed 198 cases of differentiated thyroid cancer patients in Japan and found that delaying treatment beyond 180 days increased mortality risk. The Society of Nuclear Medicine supports maintaining current regulations, citing existing scientific evidence as safe for patients and the public.
Researchers found significant improvements in lesion detection with whole-body TOF FDG PET scans, particularly in larger patients and shorter studies. TOF scans yielded better image signal-to-noise due to travel time consideration, reducing scanning time and patient motion.
A new study uses PET scans to image metabolic changes in thyroid cancer patients treated with vandetanib, a protein kinase inhibitor. The findings show that PET imaging can help define the therapy response and identify potential markers of treatment efficacy.
Researchers used PET scans to evaluate cognitive dysfunction in children with fever-induced refractory epileptic encephalopathy (FIRES), finding significant brain impairment. The study identified frontotemporal dysfunction as the cause of cognitive deterioration, paving the way for more accurate diagnosis and treatment.
A study found that PET/CT scans can predict local recurrence in lung cancer patients treated with radiofrequency ablation by analyzing lesion size, tumor type, and glucose metabolic activity. This non-invasive tool may help improve diagnosis and treatment of lung cancer.
A new study using positron emission tomography (PET) and magnetic resonance imaging (MRI) found that traumatic brain injuries lead to widespread decreases in brain functioning, particularly in the hippocampus. The research suggests a time window during which intervention could mitigate long-term neurological consequences.
A molecular imaging technique may help identify early response to treatment in cisplatin-resistant ovarian cancer, potentially reducing unnecessary side effects and offering more effective treatments. Researchers used a PET probe to monitor tumor growth in mice with human ovarian cancer.
Studies show molecular imaging improves evaluation and treatment planning for various cancers, including thyroid cancer, lymphoma, and non-small cell lung cancer. The technique allows doctors to identify disease severity and extent, providing personalized care and adjusting treatment plans accordingly.
A new imaging method can identify high-risk patients with potentially life-threatening cardiovascular conditions, helping physicians determine which patients are best suited for implantable cardioverter defibrillator therapy. This technique also helps avoid overuse or underuse of ICD treatment.
Researchers developed a novel optical imaging technique called Cerenkov Luminescence Imaging (CLI) that could lead to faster development of radiopharmaceuticals. CLI harnesses the speed of light to visualize medical isotopes, overcoming current limitations in nuclear imaging modalities.
The meeting showcased groundbreaking research and development worldwide in molecular imaging and nuclear medicine, with a focus on using molecular imaging to understand disease mechanisms and improve patient health. Key findings included advances in Alzheimer's disease identification and recurrent prostate cancer detection.
Chester A. Mathis receives SNM's 2010 Aebersold Award for his groundbreaking work on early detection in Alzheimer's disease using positron emission tomography (PET) imaging techniques. This recognition acknowledges the significant contributions of Dr. Mathis to advancing molecular imaging and nuclear medicine.
Bengt Roland Långström, a professor at Uppsala University in Sweden, has been recognized for his work in nuclear medicine. He is being honored with the Georg Charles de Hevesy Nuclear Pioneer Award for his over 20 years of experience in synthesizing and applying radiolabeled tracers for PET.
Researchers developed a non-invasive imaging technique combining PET and CT scans without bowel preparation, detecting all significant polyps found by colonoscopy. Patients preferred this method over colonoscopy due to its comfort and lack of sedation.
The Journal of Nuclear Medicine published a supplement on cardiovascular molecular imaging, discussing its potential to diagnose heart diseases earlier. The publication combines various imaging techniques, such as ultrasound, MRI, and radiotracers, to improve management of cardiovascular disease.
Research published in The Journal of Nuclear Medicine suggests that molecular imaging using 18F-FDG PET/CT can help diagnose acute and chronic aortic dissection. This non-invasive technique can provide images to determine the difference between acute and chronic dissections, helping doctors decide the best course of treatment.
The Society of Nuclear Medicine and Molecular Imaging (SNM) has received a $48,000 grant from the Agency for Healthcare Research and Quality (AHRQ) to develop research on comparative effectiveness of PET and other molecular imaging techniques. The primary emphasis will be on cancer diagnosis and management, with cardiology and neurolog...
A new imaging technique using FDG PET can help doctors plan cardiac procedures, reducing cost and improving patient outcomes. The study found a trend toward better patient outcomes when FDG PET is used in diagnostic work-up.
SNM's Clinical Trials Network has gained a new member, Eli Lilly and Company, which will support the initiative to facilitate the development of therapeutic medicines. The network aims to streamline drug discovery and integrate imaging biomarkers into clinical trials, ultimately leading to personalized diagnostics and therapies.
A new imaging technique combines ultrasound and specially modified contrast agents to detect cancer at the molecular level, allowing for early detection and potentially saving lives. The technique uses microbubbles paired with a peptide that binds to tumor vessel cells, enabling visualization of tumor activity.
A new study provides clear pediatric PET dose guidelines, allowing clinicians to calculate the optimal radiotracer dose based on a child's weight. The findings suggest that patients can receive high-quality images with reduced scan time or lower doses, minimizing radiation exposure for young children.
The Society of Nuclear Medicine and Molecular Imaging's Clinical Trials Network Workshop explored the integration of imaging biomarkers into clinical trials, emphasizing quality and standardization. Experts shared insights on overcoming challenges and harmonizing data across multiple sites.
The summit explored ways to use nanotechnology in medical imaging and therapy, focusing on targeting diseases such as cancer, neurological conditions, and cardiovascular disease. Experts discussed regulatory frameworks, design considerations, and future directions for this rapidly evolving field.
A large-scale study demonstrates that transplanted cells produced dopamine, leading to improved motor symptoms and brain function. Long-term clinical outcomes revealed sustained improvements over a four-year period.
Researchers found that a combination of single photon emission computed tomography (SPECT) and low-dose CT provided accurate diagnoses with high sensitivity and specificity. The study suggests that this technique may improve patient outcomes by reducing the mortality rate associated with untreated pulmonary embolism.
Researchers used PET scans to identify neuroinflammation in the brains of schizophrenics and migraine sufferers, shedding light on the underlying causes of these conditions. The findings have the potential to transform diagnosis and treatment options, particularly for schizophrenia.
A new molecular imaging technique using PET imaging shows promising results in evaluating and predicting the course of endometrial carcinoma. The technique combines estrogen receptor expression imaging with 18F-FDG PET to improve diagnostic accuracy, potentially saving women from unnecessary operations and biopsies.
A new study published in The Journal of Nuclear Medicine shows that PET/CT scans with the imaging agent choline can detect recurring prostate cancer sooner than conventional imaging technologies. Researchers found a strong association between PET/CT detection and PSA levels, and suggest using specific criteria to reduce unnecessary scans.
A new study found that positron emission tomography (PET) can accurately depict the extent of neuroblastoma in some patients, especially those with early-stage disease. FDG-PET imaging may also be useful in identifying malignant lesions not readily absorbable by MIBG.
Researchers used PET scans to image HER2 protein levels in breast cancer cells before and after treatment. The study showed a significant reduction in HER2 expression, indicating the treatment's effectiveness.
Researchers have developed a novel form of treatment using an alpha-particle emitting radiopeptide that targets and destroys cancer cells while sparing healthy tissue. The study found that this therapy was significantly more effective at tripling the survival rate of mice with recurrent prostate cancer compared to traditional treatments.
Researchers successfully treated basal cell carcinoma with a non-toxic radioactive patch, showing minimal scarring and no toxicity. The treatment delivered beta radiation to the cancer site, effectively eradicating the malignant cells.
Researchers at SNM's Annual Meeting discovered that combining motion-frozen technology and high-definition PET enhances cardiac imaging, revealing defects invisible to physicians. The method provides exceptional image quality and significantly changes the diagnosis of patients with heart disease.